decitabine (5-aza-2'-deoxycytidine)

10/01/2011 - "Decitabine treatment was feasible and effective in Korean patients with myelodysplastic syndrome, and the overall survival was significantly longer in patients showing hematologic improvement."
08/01/2001 - "Clinically, low-dose decitabine ameliorates cytopenias including induction of trilineage responses in approximately 50% of patients with high-risk myelodysplastic syndrome (MDS). "
07/01/2014 - "Decitabine, a demethylating drug, is the first-line treatment for myelodysplastic syndromes and gains better overall survival, which is based on epigenetic mechanism. "
02/01/2007 - "Low-dose decitabine has been studied recently in multiple clinical trials and has been shown to be effective for treatment of myelodysplastic syndromes. "
06/30/2015 - "Despite the efficacy of decitabine to myelodysplastic syndrome (MDS), there is a wide range of responses, and no definite predictive marker has been identified. "

11/01/2012 - "A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission."
07/01/2006 - "Second complete remission in an elderly patient with acute myeloid leukemia retreated with decitabine."
02/01/2010 - "Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia."
04/01/2015 - "This post hoc analysis of the DACO-016 phase III study evaluates the impact of decitabine on transfusion dependence and survival in 485 elderly patients with newly diagnosed acute myeloid leukemia (AML). "
04/01/2015 - "Decitabine reduces transfusion dependence in older patients with acute myeloid leukemia: results from a post hoc analysis of a randomized phase III study."

01/01/2013 - "After 3 cycles of decitabine and vaccine, this patient achieved a complete remission and is now 1 year from his last treatment, with no evidence of tumor in his bone marrow or other sites. "
11/01/2014 - "Importantly, low-dose decitabine and combined therapy show significant improvement in solid tumor treatment. "
01/01/2014 - "Based on these mechanisms, low-dose decitabine combined with chemoimmunotherapy may be a new treatment option for patients with refractory advanced tumors. "
11/01/2003 - "Short-term treatment of DNMT wild-type female mice with low doses of the demethylating agent 5-aza-2'-deoxycytidine decreased the incidence of neoplasms by 30%. "
06/30/2015 - "The prospective evaluations of decitabine administration schemes and tumor tissue-based pharmacodynamics effect are warranted in future trials."

01/01/2008 - "5-Aza-2'-deoxycytidine (5-AZA-CdR), a potent inhibitor of DNA methylation, is an effective agent for the treatment of leukemia. "
05/01/1993 - "Two subjects, whose blast progenitors in suspension culture were significantly inhibited by Decitabine, obtained a positive hematological response (complete or partial remission, CR or PR) and an additional patient showing a similar in vitro pattern died in induction with an hypoplastic marrow without morphological evidence of persistant leukemia. "
10/01/2014 - "This review mainly focuses on the anti-leukemia mechanism of decitabine and its clinical efficacy for AML. "
12/01/2013 - "In this study, we aimed to show that decitabine could induce specific autologous CTLs against some mouse CTAs in leukemia cells in vitro and in vivo. "
11/01/2013 - "In the present study, following treatment with a demethylating agent, decitabine, NXF2 expression was detected in the majority of the NXF2‑negative acute leukemia cell lines, but not in healthy donor samples. "

01/01/2015 - "The efficacy of low dose decitabine for treatment of ovarian cancer requires more volunteers for further investigation."
08/01/2010 - "We then confirmed our present study using SKOV3 and HEY ovarian cancer cell lines treated with the demethylating agent 5-aza-2'-deoxycytidine (5-aza-dC) to detect whether the expression of HoxA10 in the two cell lines was altered. "
09/01/2015 - "Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model."
07/15/2015 - "Pretreatment with decitabine decreased the cytotoxic activity of MEK inhibitors in KRAS-mutant ovarian cancer cells, with reciprocal downregulation of DNMT1 and MEK/ERK phosphorylation. "
07/15/2015 - "Further, we showed that KRAS genomic status predicted decitabine sensitivity in low-grade and high-grade serous ovarian cancer cells. "